Skip to main content

Table 1 Comparison of baseline characteristics between patients with T2DM with and without MACE

From: Incremental predictive value of liver fat fraction based on spectral detector CT for major adverse cardiovascular events in T2DM patients with suspected coronary artery disease

Characteristics

Total

(n = 265)

MACE (-)

(n = 214)

MACE (+)

(n = 51)

P value

Age(year)

68.00

(61.00–73.00)

67.50

(61.00–73.00)

70.00

(60.00–72.00)

0.776

Sex (female)

157(59.25)

132(61.68)

25(49.02)

0.098

BMI (kg/m2)

25.22 ± 3.72

25.14 ± 3.61

25.53 ± 4.19

0.282

T2DM life(year)

4.00

(1.00–8.00)

4.00

(1.00–7.00)

6.00

(1.50-9.00)

0.047*

Systolic pressure

(mmHg)

135.00(122.00-150.00)

135.00(122.00-150.00)

136.00(124.00-150.00)

0.668

Diastolic pressure

(mmHg)

80.00

(70.00–85.00)

80.00

(70.00–85.00)

80.00

(70.50–83.50)

0.974

Hypertension

169(63.77)

135(63.08)

34(66.67)

0.632

Smoke

78(29.43)

59(27.57)

19(37.25)

0.173

FRS%

8.00

(4.00–16.00)

6.00

(3.00–14.00)

11.00

(5.00–20.00)

0.041*

Low

145(54.72)

123(57.48)

22(43.14)

 

Middle

67(25.28)

55(25.70)

12(23.53)

 

High

53(20.00)

36(16.82)

17(33.33)

0.027*

WBC(×10^9/L)

6.23

(5.20–7.76)

6.24

(5.10–7.66)

6.23

(5.28–8.02)

0.443

Neu(×10^9/L)

3.90

(2.90–5.30)

3.85

(2.90–5.30)

3.90

(3.05–5.30)

0.465

Lym(×10^9/L)

1.60

(1.20–2.10)

1.60

(1.30–2.10)

1.50

(1.15-2.00)

0.510

Mono (×10^9/L)

0.50

(0.40–0.60)

0.40

(0.40–0.60)

0.50

(0.35–0.60)

0.308

Platelet (×10^9/L)

208.00(176.00-244.00)

205.50(172.00-244.00)

215.00(185.00-241.50)

0.449

TyG

9.19

(8.78–9.78)

9.18

(8.80–9.65)

9.34

(8.77–10.11)

0.106

SIRI

1.03

(0.65–1.84)

0.99

(0.64–1.74)

1.11

(0.73–2.01)

0.321

TC (mmol/L)

3.86

(1.94–4.83)

3.78

(1.90–4.91)

4.01

(2.19–4.78)

0.767

TG (mmol/L)

1.73

(1.19–2.74)

1.73

(1.18–2.56)

1.77

(1.22–3.91)

0.202

HDL (mmol/L)

1.09

(0.92–1.30)

1.11

(0.94–1.31)

1.02

(0.89–1.27)

0.097

LDL (mmol/L)

2.86(2.18-3.62)

2.86(2.15-3.61)

2.82(2.25-3.62)

0.840

FBG (mmol/L)

7.21

(5.77–8.69)

7.19

(5.70–8.60)

7.37

(6.38–8.92)

0.228

HbA1c (%)

7.10

(6.40–8.20)

7.00

(6.30–8.10)

7.50

(6.55–8.45)

0.069

β-receptor blocker

108(40.75)

85(39.72)

23(45.10)

0.482

Statin

134(50.57)

108(50.47)

26(50.98)

0.947

Antiplatelet drug

110(41.51)

92(42.99)

18(35.29)

0.316

CCB

95(35.85)

79(36.92)

16(31.37)

0.458

ACEI/ARB

70(26.42)

53(24.77)

17(33.33)

0.212

Insulin

75(28.30)

58(27.10)

17(33.33)

0.375

Hypoglycemic drugs

183(69.06)

151(70.56)

32(62.75)

0.278

LFF (%)

6.30

(3.20–10.50)

5.60

(2.60–8.80)

9.90

(7.10–15.00)

< 0.001*

  1. Continuous variables are expressed as standard deviation (mean) or median (interquartile range). Categorical variables are represented as number (percentages). * p < 0.05.
  2. T2DM, type 2 diabetes mellitus; MACE, major adverse cardiovascular events; BMI, body mass index; FRS, framingham risk score; WBC, white blood cell; Neu, neutrophils; Lym, lymphocyte; Mono, monocyte; TyG, triglyceride–glucose; SIRI, systemic inflammatory response index; TG, triglyceride; TC, total cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein; FBG, fasting blood glucose; HbA1c, glycated hemoglobin A1c; CCB, calcium channel blockers; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; LFF, liver fat fraction